Inclisiran a better drug in treating familial hypercholesterolemia
Familial hypercholesterolemia approximately affects 1 in 200 to 1 in 250 people in most countries and is thought to be the most common inherited condition affecting the heart and blood vessels. It is a serious cause of heart attack worldwide and causing a serious threat in global health management.
The ORION- 4 trial in the Journal of the American College of Cardiology reveals that pooled safety and efficacy data of inclisiran, when given twice yearly in addition to maximally tolerated statin therapy with or without other LDL-Cholesterol lowering agents, is an effective, safe, and well-tolerated treatment to lower LDL-Cholesterol in adults with heterozygous familial hypercholesterolemia, atherosclerotic cardiovascular disease, or atherosclerotic cardiovascular disease risk equivalents.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd